



European Society for Immunodeficiencies



FLORENCE | ITALY
October 3-6, 2012



th
Biennial
Meeting

of the European Society for Immunodeficiencies

WAY FORWARD
IN BETTER
UNDERSTANDING
PID

HIGHLIGHTS

Dr. Nizar MAHLAOU, MD, MSc, MPH
CEREDIH: The French National Reference Center for PID
Paediatric Immuno-Haematology Unit
Necker-Enfants malades University Hospital, Paris, France



Contact: nizar.mahlaoui@nck.aphp.fr

Website: www.ceredih.fr

As of Sep. 26th, 2012

Inclusions in ESID - 97 centres (n=16,083)


France (CEREDIH), n=4,660 (29%)



France: 65 millions inhab.
(Germany: 81/UK: 58/Italy: 60)

Estimation de la prévalence des patients avec DIH en France

Prévalence nationale : 5.24 /10e5 (3352 patients vivants) le 24 / 09 / 2012




Prevalence disparities/

Geographical variation

Data collection (CEREDIH)

- Diagnosis (low/up?), Un (adult patients+++)?
- Acces to care: Local inadequations in term of access to health care services?
- Exhaustivity
- Consanguinity?
- Others...?

Survival data



Highlights

- New genes: CMC, SCID/CID, NK def, DC def
- Congenital Asplenia
- PID and beyond
 - IBD (IL10(R), CGD, XIAP,...) / Crohn's Disease (CF...)
 - Microbiota
- CDG2 and HIV...
- Anti-Infectious prophylaxis Recommendations for every PID (CEREDIH work).
- Report on the first case of pregnancy on PegADA
- NBS for SCID (EU/Many other countries/Update on USA experience)
- AI cytopenia (Ritux in CVID, eltrombopag in WAS,...)
- Gene Therapy protocols